mTOR: A double-edged sword for diabetes.

Area of Science:

• Metabolic and immune disorders
• Cellular signaling pathways
• Diabetes pathogenesis

Background:

• Diabetes involves complex metabolic and immune dysregulation.
• The serine-threonine protein kinase, mammalian target of rapamycin (mTOR), links metabolism and immunity.
• mTOR is a key regulator of fuel metabolism and cell function in pancreatic beta cells and immune cells.

Purpose of the Study:

• To review the dual role of mTOR signaling in pancreatic beta cells and immune cells.
• To explore the implications of mTOR in diabetes pathogenesis.
• To discuss potential therapeutic strategies targeting mTOR in diabetes.

Main Methods:

• Literature review focusing on mTOR signaling in diabetes.
• Analysis of mTOR's role in pancreatic beta cell function.
• Examination of mTOR's impact on immune cell metabolism and function.

Main Results:

• mTOR activation in beta cells can promote growth and insulin secretion, counteracting diabetes.
• mTOR activation in immune cells can impair beta cell function and contribute to diabetes development.
• mTOR exhibits both anti-diabetic and pro-diabetic effects depending on cellular context.

Conclusions:

• mTOR signaling plays a critical, context-dependent role in diabetes pathogenesis.
• Understanding mTOR's dual functions is crucial for developing effective diabetes treatments.
• Targeting mTOR pathways may offer novel therapeutic avenues for managing diabetes.